Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus

Internal Medicine Journal

Volumn 35, Issue 10, 2005, Pages 592-598

  Seed, Clive R ^a   Kiely, P ^a   Keller, A J ^a  

^a AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

Author keywords

Blood donation; HBV; HCV; HIV; Risk assessment

Indexed keywords

ARTICLE; AUSTRALIA; BLOOD TRANSFUSION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS; INFECTION RISK; POSTTRANSFUSION HEPATITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; SCREENING; TORQUE TENO VIRUS; VASCULARIZATION; VIRUS TRANSMISSION;

AUSTRALIA; BLOOD TRANSFUSION; CONFIDENCE INTERVALS; HEPACIVIRUS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C ANTIGENS; HIV; HIV INFECTIONS; HTLV-I ANTIGENS; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; INCIDENCE; MODELS, THEORETICAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RNA, VIRAL;

EID: 27644546392     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2005.00926.x     Document Type: Article

References (32)

1. Busch M. Closing the window on viral transmission. In: Stramer SL, ed. Blood Safety in the New Millennium. Bethesda: AABB Press 2001;33-54.
2. Correll PK, Law MG, Seed CR, Gust A, Buring M, Dax EM et al. Variant Creutzfeldt-Jakob disease in Australian blood donors: estimation of risk and the impact of deferral strategies. Vox Sang 2001; 81: 6-11.
3. Seed CR, Cheng A, Ismay SL, Bolton WV, Kiely P, Cobain TJ et al. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 2002; 42: 1365-72.
4. Whyte GS, Savoia HF. The risk of transmitting HCV, HBV or HIV by blood transfusion in Victoria. Med J Aust 1997; 166: 584-6.
5. Dax EM, Healey DS, Crofts N. Low risk of HIV-1 infection from blood donation: a test-based estimate. Med J Aust 1992; 157: 69-70.
6. Glynn SA, Kleinman SH, Wright DJ, Busch MP. International application of the incidence rate/window period model. Transfusion 2002; 42: 966-72.
7. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42: 975-9.
8. Lelie PN, van Drimmelen HA, Cuypers HT, Best SJ, Stramer SL, Hyland C et al. Sensitivity of HCV RNA and HIV RNA blood screening assays. Transfusion 2002; 42: 527-36.
9. Kleinman S, Busch MP, Korelitz JJ, Schreiber GB. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev 1997; 11: 155-72.
10. Muller-Breitkreutz K. Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997. EPFA Working Group on Quality Assurance. Vox Sang 2000; 78: 149-57.
11. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, Weiblen BJ et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998; 280: 42-8.
12. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45: 254-64.
13. Kleinman S, Busch MP. The risks of transfusion transmitted infection: direct estimation and mathematical modelling. Baillieres Best Pract Res Clin Haematol 2000; 13: 631-49.
14. Murthy KK, Henrard DR, Eichberg JW, Cobb KE, Busch MP, Allain JP et al. Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission. Transfusion 1999; 39: 688-93.
15. Biswas R, Busch MP, Hsia C, Wright DJ, Laycock ME, Fiebig EW et al. Comparative sensitivity of HBV NAT and HBsAg donor testing. Transfusion 2001; 41: 8S.
16. Stramer SL, Brodsky JP, Preston S, Kuhns MC, Pierce MP, Smith RI. Comparative sensitivity of HBsAg and HBV NAT. Transfusion 2001; 41: 8S.
17. Mimms LT, Mosley JW, Hollinger FB, Aach RD, Stevens CE, Cunningham M et al. Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. BMJ 1993; 307: 1095-7.
18. Manns A, Wilks RJ, Murphy EL, Haynes G, Figueroa JP, Barnett M et al. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer 1992; 51: 886-91.
19. Soldan K, Barbara JA, Ramsay ME, Hall AJ. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001. Vox Sang 2003; 84: 274-86.
20. Chiavetta JA, Escobar M, Newman AM, He Y, Driezen P, Decks S et al. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000. CMAJ 2003; 169: 767-73.
21. National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS viral hepatitis and sexually transmissible infections in Australia - annual surveillance report. Sydney: University of New South Wales 2002; 7-8.
22. Korelitz JJ, Busch MP, Kleinman SH, Williams AE, Gilcher RO, Ownby HE et al. A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study. Transfusion 1997; 37: 634-40.
23. Allain JP. Occult hepatitis B virus infection. Transfus Clin Biol 2004; 11: 18-25.
24. Busch MP. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? Transfus Clin Biol 2004; 11: 26-32.
25. Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA et al. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 2004; 86: 28-40.
26. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003; 43: 721-9.
27. AuBuchon JP, Littenberg B. A cost-effectiveness analysis of the use of a mechanical barrier system to reduce the risk of mistransfusion. Transfusion 1996; 36: 222-6.
28. Calman K. The Health of the Nation. Br J Hosp Med 1996; 56: 125-6.
29. Jacobs MR, Palavecino E, Yomtovian R. Don't bug me: the problem of bacterial contamination of blood components - challenges and solutions. Transfusion 2001; 41: 1331-4.
30. Williamson LM, Lowe S, Love EM, Cohen H, Soldan K, McClelland DB et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. BMJ 1999; 319: 16-19.
31. Barbara J, Eglin R. Genome detection and transfusion: setting the scene. Transfus Med 2002; 12: 227-8.
32. Simmonds P, Kurtz J, Tedder RS. The UK blood transfusion service: over a (patent) barrel? Lancet 2002; 359: 1713-14.